Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum-Reference-Cited by-同舟云学术

Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum

Published:2024 Issue:23 Volume:16 Page:3720-3731
ISSN:1759-9660
Container-title:Analytical Methods
language:en
Short-container-title:Anal. Methods

Author:

Cao Rongrong¹^ORCID,Xu Songlin¹,Yu Zhirui²,Xu Liang³^ORCID,Ge Zhiqiang¹,Huo Qianyu⁴,Zhu Guoqing⁴^ORCID,Qiao Bin¹⁵

Affiliation:

1. School of Chemical Engineering, Tianjin University, Tianjin 300072, China

2. Safety and Technology Center of Industry Products, Tianjin Custom, Tianjin, 300308, China

3. Tianjin Medical College, Tianjin 300070, China

4. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China

5. Frontiers Research Institute for Synthetic Biology, Tianjin University, Tianjin 300072, China

Abstract

Procedures for integrating protein L-immobilized magnetic bead capture with LC-MS/MS for mAb quantification in mouse serum.

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/AY/D4AY00433G

Reference43 articles.

1. Muromonab CD3

2. The Antibody Society , https://www.antibodysociety.org , accessed 15 Jan 2024

3. M. P.Lefranc , Cold Spring Harbor Protocols , 2011 , vol. 2011 , p. 595 , DOI: 10.1101/pdb.top115

4. Antibodies to watch in 2024

5. Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028